{"entity":{"id":"nct05801237","kind":"trial","name":"PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor","aka":[],"tldr":"A phase 1/2 trial of PE0116&PE0105 in advanced solid tumours, run by Shanghai HyaMab Biotech Co.,Ltd., now recruiting.","summary":"PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor is a phase 1/2 interventional study registered as NCT05801237 by Shanghai HyaMab Biotech Co.,Ltd., with 120 participants planned, started 2023-09-21 and due to reach its primary completion in 2026-09. Interventions recorded: PE0116&PE0105.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05801237","url":"https://clinicaltrials.gov/study/NCT05801237"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05801237","phase":"1/2","setting":"A Phase Ib/II Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor","sponsor":"Shanghai HyaMab Biotech Co.,Ltd.","enrolled":120,"outcomes":[]},"route":"/trials/nct05801237/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}